ATE279945T1 - Verwendung von coxiella bakterien zur behandlung von autoimmunkrankheiten - Google Patents

Verwendung von coxiella bakterien zur behandlung von autoimmunkrankheiten

Info

Publication number
ATE279945T1
ATE279945T1 AT97906937T AT97906937T ATE279945T1 AT E279945 T1 ATE279945 T1 AT E279945T1 AT 97906937 T AT97906937 T AT 97906937T AT 97906937 T AT97906937 T AT 97906937T AT E279945 T1 ATE279945 T1 AT E279945T1
Authority
AT
Austria
Prior art keywords
autoimmune diseases
coxiella
treat autoimmune
mammal
useful
Prior art date
Application number
AT97906937T
Other languages
English (en)
Inventor
William Butler Cowden
Kevin John Lafferty
Lawrence Scott Gazda
Original Assignee
Univ Australian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Australian filed Critical Univ Australian
Application granted granted Critical
Publication of ATE279945T1 publication Critical patent/ATE279945T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT97906937T 1996-03-14 1997-03-14 Verwendung von coxiella bakterien zur behandlung von autoimmunkrankheiten ATE279945T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPN8703A AUPN870396A0 (en) 1996-03-14 1996-03-14 Treatment of auto-immune insulin-dependent diabetes mellitus
PCT/AU1997/000161 WO1997033614A1 (en) 1996-03-14 1997-03-14 Use of coxiella bacteria to treat autoimmune disease

Publications (1)

Publication Number Publication Date
ATE279945T1 true ATE279945T1 (de) 2004-11-15

Family

ID=3793016

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97906937T ATE279945T1 (de) 1996-03-14 1997-03-14 Verwendung von coxiella bakterien zur behandlung von autoimmunkrankheiten

Country Status (9)

Country Link
US (1) US6790450B1 (de)
EP (1) EP0886528B1 (de)
JP (1) JP2000506172A (de)
AT (1) ATE279945T1 (de)
AU (1) AUPN870396A0 (de)
DE (1) DE69731284D1 (de)
NZ (2) NZ503143A (de)
WO (1) WO1997033614A1 (de)
ZA (1) ZA972232B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057534A2 (en) * 2000-02-04 2001-08-09 Bioseek Compositions and methods for reducing autoimmunity
CN1218750C (zh) 2003-06-06 2005-09-14 长春生物制品研究所 皮内注射用重组乙型肝炎卡介苗联合疫苗及制备方法
GB201517019D0 (en) * 2015-09-25 2015-11-11 Sec Dep For Health The Coxiella burnetii antigens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation
US6066333A (en) * 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation
AU5960096A (en) * 1995-06-07 1996-12-30 Nexstar Pharmaceuticals, Inc. Method to use superantigens to target subpopulations of t ce lls

Also Published As

Publication number Publication date
NZ331536A (en) 2000-07-28
JP2000506172A (ja) 2000-05-23
AUPN870396A0 (en) 1996-04-04
EP0886528A4 (de) 1999-06-02
US6790450B1 (en) 2004-09-14
ZA972232B (en) 1997-11-18
NZ503143A (en) 2001-06-29
DE69731284D1 (de) 2004-11-25
EP0886528A1 (de) 1998-12-30
EP0886528B1 (de) 2004-10-20
WO1997033614A1 (en) 1997-09-18

Similar Documents

Publication Publication Date Title
AU2369595A (en) In vitro growth of functional islets of langerhans and in vivo uses thereof
DE69100364D1 (de) Verwendung von N-Myristoyl-(S)-Phenylalanin zur Herstellung eines Medikaments zur Behandlung von Krankheiten mittels Hemmung der Myristoylierung.
ES2175087T3 (es) Compuestos triciclicos utiles en el tratamiento de trastornos de proliferacion celular.
NZ597965A (en) Methods of preparing and using stem cell compositions and kits comprising the same
DE59905954D1 (de) Dialkylfumarate zur behandlung von autoimmunerkrankungen
ATE204176T1 (de) Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven
ATE218350T1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
BG96329A (bg) Модифициран биологичен материал
TR199903142T2 (xx) Pankreas dokusu adac��� transplantasyonu i�in CD154 blokaj tedavisi.
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
NO992569D0 (no) FremgangsmÕter for Õ hindre podingsforkastelse i transplantasjon og for fremstilling av en universell genterapi vertcelle ved Õ anvende lymfocytt aktivering (LAG-3)
DE69325029D1 (de) Verwendung der il-10 zur verhinderung des insulin-abhängigen diabetes mellitus
RU96121980A (ru) Биопрепарат фитоспорин для защиты растений от болезней
DE60313356D1 (de) Verwendungvon dextransulfat zur behandlung von ibmir
ATE279945T1 (de) Verwendung von coxiella bakterien zur behandlung von autoimmunkrankheiten
FI971427A0 (fi) Peptidit ja niitä sisältävät farmaseuttiset koostumukset
Angus The biogeography of land snails in the islands of the Gulf of Guinea
DE69821506D1 (de) Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort
MXPA02005069A (es) Agentes de enlace especificos para t3 y metodos para su uso.
ATE264112T1 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
ES2108122T3 (es) Composicion a base de amilina o de un analogo de amilina conteniendo opcionalmente insulina, para el tratamiento de la anorexia y de las patologias asociadas.
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
Soldan Adaptation of the subimaginal life span of Cloeon(Ephemeroptera, Baetidae) in the arid areas of North Africa and the Canary Islands.
ATE135232T1 (de) Pharmazeutische zusammensetzungen zur behandlung von b-zell-entartungen
DE69832796D1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties